ArticlePloS one2020

Cost-effectiveness of alectinib compared to crizotinib for the treatment of first-line ALK+ advanced non-small-cell lung cancer in France.

Marine Sivignon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.